Bavar­i­an Nordic lands break­through des­ig­na­tion for RSV vac­cine; Ucel­lo clos­es Se­ries A to ad­vance CAR-T ther­a­pies

The FDA has grant­ed Bavar­i­an Nordic a Break­through Ther­a­py Des­ig­na­tion for its vac­cine to pre­vent low­er res­pi­ra­to­ry tract dis­ease caused by res­pi­ra­to­ry syn­cy­tial virus.

The des­ig­na­tion will al­low Bavar­i­an to work more close­ly with the FDA for the de­vel­op­ment and the re­view of the vac­cine. The vac­cine is be­ing de­vel­oped for pa­tients aged 60 and old­er.

Break­through des­ig­na­tion is de­signed to ex­pe­dite the re­view of med­i­cines in­tend­ed to treat se­ri­ous con­di­tions. The as­sess­ment was based off of clin­i­cal ev­i­dence that showed the can­di­date might show a sig­nif­i­cant im­prove­ment over an ex­ist­ing ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER